

# Nadja Zaborsky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7073370/publications.pdf>

Version: 2024-02-01

32  
papers

500  
citations

840776

11  
h-index

713466

21  
g-index

34  
all docs

34  
docs citations

34  
times ranked

859  
citing authors

#	ARTICLE	IF	CITATIONS
1	Disease-related blood-based differential methylation in cystic fibrosis and its representation in lung cancer revealed a regulatory locus in <i>PKP3</i> in lung epithelial cells. <i>Epigenetics</i> , 2022, 17, 837-860.	2.7	1
2	Detecting Bacterial–Human Lateral Gene Transfer in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1094.	4.1	3
3	RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 1053-1063.	7.2	17
4	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors. <i>Pharmaceuticals</i> , 2021, 14, 89.	3.8	9
5	Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies. <i>Cancers</i> , 2021, 13, 650.	3.7	4
6	SAMHD1 restrains aberrant nucleotide insertions at repair junctions generated by DNA end joining. <i>Nucleic Acids Research</i> , 2021, 49, 2598-2608.	14.5	15
7	AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL. <i>Cancers</i> , 2021, 13, 2619.	3.7	5
8	Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tcl1 Mouse Model for Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6648.	4.1	1
9	CAR T-Cell Therapy in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8996.	4.1	73
10	A POLE Splice Site Deletion Detected in a Patient with Biclonal CLL and Prostate Cancer: A Case Report. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9410.	4.1	2
11	Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer. <i>Pancreatology</i> , 2021, 21, 1466-1471.	1.1	6
12	Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma. , 2021, 9, e002170.		3
13	Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2775.	2.4	10
14	RNA Editing Alters miRNA Function in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020, 12, 1159.	3.7	11
15	Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity. <i>Molecular Oncology</i> , 2020, 14, 1930-1946.	4.6	21
16	TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 2498-2502.	7.2	2
17	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2856.	4.1	31
18	The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 609409.	2.8	15

#	ARTICLE	IF	CITATIONS
19	B-cell-specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion. <i>Blood</i> , 2019, 134, 1717-1729.	1.4	17
20	Next Generation Sequencing in AML "On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?". <i>Cancers</i> , 2019, 11, 252.	3.7	44
21	BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF- $\kappa$ B Nuclear Translocation. <i>Clinical Cancer Research</i> , 2019, 25, 1901-1912.	7.0	23
22	Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development. <i>Leukemia</i> , 2019, 33, 957-968.	7.2	22
23	Mouse models to decipher anti-tumor immunity. <i>Oncotarget</i> , 2019, 10, 5005-5006.	1.8	0
24	Imprecision and DNA Break Repair Biased towards Incompatible End Joining in Leukemia. <i>Molecular Cancer Research</i> , 2018, 16, 428-438.	3.4	11
25	Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. <i>Annals of Hematology</i> , 2018, 97, 1825-1839.	1.8	6
26	TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. <i>Oncimmunology</i> , 2018, 7, e1371399.	4.6	55
27	CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells. <i>Oncotarget</i> , 2016, 7, 49459-49469.	1.8	8
28	B cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T cell clonality in chronic lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, e307-10.	3.5	10
29	Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the <scp>TCL</scp> 1 transgenic mouse model. <i>British Journal of Haematology</i> , 2015, 170, 515-522.	2.5	38
30	Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. <i>Haematologica</i> , 2014, 99, 67-69.	3.5	35
31	Targeting Dysfunctional Myeloid Cells Delays Disease Development and Improves Immune Function in a CLL Mouse Model. <i>Blood</i> , 2014, 124, 3298-3298.	1.4	0
32	The Transcription Factor IRF4 Is Crucial for CLL Progression and Regulates Survival and Proliferation in a Microenvironment Related Manner. <i>Blood</i> , 2014, 124, 1973-1973.	1.4	0